Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.
2 July 2018

Vator Securities advises AlzeCure Pharma on SEK 40 million directed share issue

Vator Securities acted as Sole Bookrunner and Advisor in connection with the transaction raising SEK 40 million.

AlzeCure Pharma is a pre-clinical, biopharmaceutical company with first-in-class and/or best-in-class proprietary and novel targeted small molecule treatments for neurodegenerative diseases with a primary target on Alzheimer’s Disease. The five primary candidates are derived from two platforms – NeuroRestore and Alzstatin. The first candidate is estimated to enter clinical trials before year-end 2018, and all five candidates are estimated to be in clinical trials during 2020.

AlzeCure’s team has extensive experience from Big Pharma and formed an integral part of the Neurological department at AstraZeneca. The team’s research at AstraZeneca led to several commercial successes, including being integral in developing a BACE inhibitor licensed to Eli Lilly in 2014 for a total sum of up to USD 500m.

AlzeCure applies a genetically and biomarker driven development, implying utilisation of breakthrough research to develop the best candidates, select the right patient population with the right disease stage for clinical trials which increases the probability of success. The deep understanding of the genetic pathways and disease biology enables additional indications related to e.g. Traumatic Brain Injury, Sleep disorders, Parkinson’s Disease as well as other non-cognitive indications such as Neurotrophic Keratitis, depression and other undisclosed indications.

Pre-clinical studies imply a strong safety profile for both platforms which significantly enhances the probability of success in the early clinical trials.

Alzheimer is a 100% fatal disease and the commercial potential for a disease-modifying therapy alone is USD +10bn in annual sales. The science is now breaking open, and the time is right to discover and develop effective medicines for neurodegeneration.

The funds raised from the share issue will be used to commit to the Phase I trials for the first compound, ACD855.

________________________________________

For further information,

Homan Panahi, CEO, Vator Securities

Tel: +46 763-98 96 66

E-post: homan@vatorsec.se

About Vator Securities

Vator Securities provides an extensive range of capital markets and advisory services to cutting-edge public and private growth companies with an emphasis on the Life Sciences, Medical Technology and Diagnostics industries. Vator Securities executes on opportunities that accelerate growth for its client companies while delivering results to the firm’s sophisticated investor clientele. Vator Securities distinguishes itself by the firm’s ability to raise capital from traditional institutional investors, as well as from its proprietary global network of family office and high net worth investors. Vator Securities was founded in Stockholm in 2009 and the firm is primarily an equity partnership.